Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
Other Sizes |
|
ln Vitro |
VI 16832 is a type I kinase inhibitor with a broad spectrum [1]. More than 8500 phosphopeptides were found by phosphoproteomic analysis of VI 16832-enriched fractions in MV4-11, HCT116, or 435S cells. These correspond to 212 distinct protein kinase superfamily members, or around 1700 distinct phosphopeptide compounds. The overall number of discovered phosphorylation sites on protein kinases was greatly increased by analysis of VI 16832 retained proteins from three cancer cell lines. When calculating the total phosphopeptide intensities to determine the quantity of protein enriched in VI 16832, protein kinases accounted for more than 80% of the total [2].
|
---|---|
References |
Molecular Formula |
C22H25N5O2
|
---|---|
Molecular Weight |
391.466204404831
|
Exact Mass |
391.2
|
CAS # |
1430218-51-1
|
PubChem CID |
89510076
|
Appearance |
Light yellow to yellow solid powder
|
Density |
1.3±0.1 g/cm3
|
Boiling Point |
611.9±65.0 °C at 760 mmHg
|
Flash Point |
323.9±34.3 °C
|
Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
Index of Refraction |
1.679
|
LogP |
1.87
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
6
|
Rotatable Bond Count |
6
|
Heavy Atom Count |
29
|
Complexity |
620
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
RCSLGYIVHUXZCI-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C22H25N5O2/c23-9-10-29-18-6-4-17(5-7-18)25-22-24-13-16-3-8-20(28)27(21(16)26-22)19-12-14-1-2-15(19)11-14/h3-8,13-15,19H,1-2,9-12,23H2,(H,24,25,26)
|
Chemical Name |
2-[4-(2-Aminoethoxy)anilino]-8-(3-bicyclo[2.2.1]heptanyl)pyrido[2,3-d]pyrimidin-7-one
|
Synonyms |
VI16832 VI 16832 VI-16832
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~85.14 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5545 mL | 12.7724 mL | 25.5447 mL | |
5 mM | 0.5109 mL | 2.5545 mL | 5.1089 mL | |
10 mM | 0.2554 mL | 1.2772 mL | 2.5545 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.